Annals of Oncology Advance Access published online on August 22, 2007
Annals of Oncology, doi:10.1093/annonc/mdm268
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer
1 Research Unit in Medical Senology at the Department of Medicine
2 Unit of Quality Control
3 Division of Epidemiology and Biostatistics
4 Division of Pathology and Laboratory Medicine
5 Division of Senology, European Institute of Oncology
6 University of Milan School of Medicine, Milan, Italy
* Correspondence to: Marco Colleoni MD, Research Unit in Medical Senology at the Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy. Tel: +39–02–57489439; Fax: +39–02–574829212; E-mail address: marco.colleoni{at}ieo.it
Background: The clinical relevance of the degree of peritumoral vascular invasion (PVI) in patients with no or limited involvement of the axillary nodes is unknown.
Materials and methods: 2606 consecutive patients with pT1-3, pN0 (1586)-1a (1020) and M0, operated and counseled for medical therapy from 1/2000 to 12/2002, were prospectively classified according to the degree of PVI: absent (2017, 77.4%), focal (368, 14.1%), moderate (51, 2.0%) and extensive (170, 6.5%).
Results: Patients with extensive PVI were more likely to be younger, to have larger tumors, high tumor grade, axillary-positive nodes, high Ki-67 expression and HER2/neu over-expression compared with patients having less PVI (P for trend, <0.0001). In patients with node-negative disease a statistically significant difference in disease-free survival (DFS), risk of distant metastases and overall survival (OS) was observed at the multivariate analysis for extensive PVI versus no PVI (hazard ratios: 2.11, 95% CI, 1.02 to 4.34, P = 0.04 for DFS; 4.51, 95% CI, 1.96 to 10.4, P< 0.001 for distant metastases; 3.55, 95% CI, 1.24 to 10.1, P = 0.02 for OS).
Conclusions: The extent of vascular invasion should be considered in the therapeutic algorithm in order to properly select targeted adjuvant treatment.
peritumoral vascular invasion, breast cancer, prognostic factor
Received for publication January 19, 2007. Revision received March 9, 2007. Accepted for publication April 30, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Viale, A. Giobbie-Hurder, B. A. Gusterson, E. Maiorano, M. G. Mastropasqua, A. Sonzogni, E. Mallon, M. Colleoni, M. Castiglione-Gertsch, M. M. Regan, et al. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer Ann. Onc., July 24, 2009; (2009) mdp317v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ejlertsen, M.-B. Jensen, F. Rank, B. B. Rasmussen, P. Christiansen, N. Kroman, M. E. Kvistgaard, M. Overgaard, D. B. Toftdahl, H. T. Mouridsen, et al. Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer J Natl Cancer Inst, May 20, 2009; 101(10): 729 - 735. [Abstract] [Full Text] [PDF]
|
|